{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-007811","form_type":"8-K","ticker":"RZLT","cik":"0001509261","company_name":"Rezolute, Inc.","filed_at":"2024-01-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.420647+00:00","generated_at":"2026-06-06T15:52:41.820444+00:00","sec_items":["3.02","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Rezolute appoints Daron Evans as CFO; receives UK Innovation Passport for RZ358","bullets":["Daron Evans appointed CFO, effective Jan 23, 2024; base salary $275,000, target bonus 50%.","Received inducement grant of 275,000 stock options at $1.02 (closing price), vesting over 4 years.","UK MHRA awarded Innovation Passport to RZ358 for congenital hyperinsulinism treatment.","Innovation Passport is entry to ILAP, aims to accelerate time to market and patient access.","Phase 3 study for RZ358 initiated; Phase 2 RZ402 data expected Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-007811","json":"https://secwatch.observer/filing/0001104659-24-007811.json","markdown":"https://secwatch.observer/filing/0001104659-24-007811.md","text":"https://secwatch.observer/filing/0001104659-24-007811.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509261/000110465924007811/0001104659-24-007811-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509261/000110465924007811/tm244315d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T15:52:41.820444+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e95112eb6b","claim":"Daron Evans was appointed as Chief Financial Officer at Rezolute, Inc..","evidence_excerpt":"On January 23, 2024, the Company’s Board of Directors approved the appointment of Mr. Evans, 50 years of age, to serve as the Company’s Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1509261/000110465924007811/0001104659-24-007811-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}